Intellectual Property & Patents

Intellectual Property

GreenWay Herbal Products, LLC is an intellectual property holding and licensing company. Our estate covers methods of using the equally paired molecule formula — an approximately 1:1 equimolar composition of cannabidiol and cannabidiolic acid, with THC and THCA not present — and additionally, compositions and methods combining it with omega fatty acids.

The estate originates from research GreenWay funded at Middle Tennessee State University beginning in 2016. The priority application, U.S. Provisional 62/840,972, was filed April 30, 2019 and assigned to GreenWay Herbal Products, LLC, which owns the estate.

Family 1: Cannabinoid Compositions and Methods of Using

International application PCT/US2020/030777, published as WO 2020/223510 A1, filed April 30, 2020.

Granted

EP 3 962 296 B1 (Appl. 20798958.3), granted April 29, 2026 — validated in Belgium, Denmark, France, Germany, Ireland, Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom

  • United States

    • US 12,496,307 B2 (Appl. 17/594,830), granted December 16, 2025

  • United Kingdom

    • GB 2597163 B (Appl. GB2115666.6), granted July 26, 2023

    • GB 2614634 B (Appl. GB2304091.8), granted November 8, 2023

US 12,496,307 claims methods of treating inflammation or autoimmunity — including rheumatoid arthritis, Crohn's disease, multiple sclerosis, psoriatic disease, scleroderma and systemic lupus — by administering a pharmaceutical composition whose cannabinoid mixture is an approximately 1:1 equimolar mixture of cannabidiol and cannabidiolic acid containing 1% or less of other cannabinoids.

Pending

  • United States — 19/327,282, continuation of 17/594,830 (published US 2026/0000687 A1)

  • United States — 19/327,713, divisional of 17/594,830 (published US 2026/0000688 A1)

  • Europe — 25219044.2, divisional of EP 3 962 296 (published EP 4 678 189)

  • Canada (CA 3132856)

  • Israel — IL 287456

  • Israel — IL 318621, divisional of IL 287456

  • Thailand — 2101006714

Family 2: Cannabinoid and Omega Fatty Acid Compositions and Methods of Using

Granted

- United States — US 12,678,451 B2 (Appl. 18/164,044), granted July 14, 2026

US 12,678,451 claims pills combining an approximately 1:1 equimolar mixture of cannabidiol and cannabidiolic acid with an omega fatty acid component at about 1:1,250 to 1:3,750 by weight, and methods of administering them.

Allowed

- United States — 17/931,249 (published US 2023/0015268 A1) — Notice of Allowance, October 20, 2026

The allowed claims cover pills combining an approximately 1:1 equimolar mixture of cannabidiol and cannabidiolic acid with DHA and EPA at about 1:375 to 1:3,750 by weight.

Pending

- Europe — 23866300.9, regional phase of PCT/US2023/061944

Development

We license the estate for pharmaceutical development.

[updated: 11/02/2026]